Department of Obstetrics and Gynecology, Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biology and Anatomical Sciences, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
JBRA Assist Reprod. 2021 Jul 21;25(3):368-372. doi: 10.5935/1518-0557.20200077.
The use of gonadotropin-releasing hormone agonist (GnRHa) as an alternative for human chronic gonadotropin (hCG) trigger has potential benefits, but the optimal luteal phase support (LPS) following GnRHa trigger remains to be elucidated. We aimed to investigate a new strategy (daily GnRH agonist for LPS following GnRH agonist trigger) as an alternative for the conventional approach to the patients undergoing intracytoplasmic sperm injection (ICSI).
In this randomized controlled trial study, 44 ICSI patients were randomly assigned into two groups: group 1, patients received standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS); group 2, patients received a dose of GnRHa (0.2 mg) for ovulation trigger and subcutaneous injection of GnRHa bid (0.2 mg) for LPS.
The pregnancy, miscarriage, and live birth rates for the patients undergoing LPS following the GnRHa trigger were similar to those of patients undergoing the standard strategy.
We showed that a daily subcutaneous injection of GnRHa for LPS following the GnRHa trigger can be successfully performed as an alternative to the standard strategy, with comparable pregnancy and live birth rates in ICSI patients.
促性腺激素释放激素激动剂（GnRHa）替代人绒毛膜促性腺激素（hCG）触发排卵具有潜在益处，但最佳黄体支持（LPS）方案仍需进一步阐明。我们旨在研究一种新策略（GnRHa 触发后每日 GnRH 激动剂用于 LPS）作为接受胞浆内精子注射（ICSI）患者的常规方法的替代方案。
在这项随机对照试验研究中，将 44 名 ICSI 患者随机分为两组：组 1，患者接受标准方案（hCG 触发[10000IU]和黄体酮 bid[400mg/BD]用于 LPS）；组 2，患者接受 GnRHa（0.2mg）触发排卵，并皮下注射 GnRHa bid[0.2mg]用于 LPS。
GnRHa 触发后 LPS 的妊娠、流产和活产率与接受标准方案的患者相似。
我们表明，GnRHa 触发后每日皮下注射 GnRHa 用于 LPS 可以成功替代标准方案，在 ICSI 患者中具有相似的妊娠和活产率。
